ABBV · 8-K · 20261030PR000033

Product Launch and Transition

AbbVie Inc. · 2026-10-30 · Importance 59 · Surprise 82

AbbVie reported third-quarter Vyalev revenues of $286 million, with growth exceeding 100% versus the prior-year quarter. Nine-month Vyalev revenues were $743 million and also increased by more than 100%. Linzess revenue grew 25.2% to $917 million for the first nine months, while Mavyret fell 10.1% to $911 million and Creon declined 5.4% to $1.067 billion. These results identify substantial growth in Vyalev and Linzess alongside declines in Mavyret and Creon.

Key facts

• AbbVie presented Phase 1 data for ABBV-295, a long-acting amylin analog in development for obesity, showing an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure. source
• ABBV-295 data support evaluation at dosing intervals beyond weekly administration, including every-other-week and monthly regimens. source